## **Cornelis F M Sier**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4472418/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. British Journal of Cancer, 1996, 74, 413-417.	6.4	268
2	Matrix Metalloproteinase-14 (MT1-MMP)–Mediated Endoglin Shedding Inhibits Tumor Angiogenesis. Cancer Research, 2010, 70, 4141-4150.	0.9	231
3	Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts. Oncogene, 2014, 33, 97-107.	5.9	216
4	Use and efficacy of bone morphogenetic proteins in fracture healing. International Orthopaedics, 2011, 35, 1271-1280.	1.9	215
5	Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood, 2000, 96, 4091-4095.	1.4	185
6	VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. European Journal of Cancer, 2008, 44, 1904-1913.	2.8	177
7	Urokinase receptor and colorectal cancer survival. Lancet, The, 1994, 344, 401-402.	13.7	174
8	Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis. Clinical Cancer Research, 2018, 24, 6331-6344.	7.0	138
9	Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. European Journal of Cancer, 2007, 43, 1869-1876.	2.8	128
10	Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Digestive and Liver Disease, 2007, 39, 733-739.	0.9	123
11	Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Digestive and Liver Disease, 2005, 37, 584-592.	0.9	116
12	Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage. Brain, 2001, 124, 1978-1988.	7.6	114
13	Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. British Journal of Cancer, 2006, 95, 744-751.	6.4	105
14	Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Letters, 2000, 475, 52-56.	2.8	103
15	Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood, 2001, 97, 3123-3131.	1.4	100
16	Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer. BMC Cancer, 2019, 19, 284.	2.6	95
17	Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. British Journal of Cancer, 2006, 94, 1035-1040.	6.4	88
18	Superoxide dismutases in relation to the overall survival of colorectal cancer patients. British Journal of Cancer, 1998, 78, 1051-1057.	6.4	84

#	Article	IF	CITATIONS
19	Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins. Biomarkers in Cancer, 2016, 8, BIC.S38542.	3.6	82
20	ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Science Advances, 2019, 5, eaax2770.	10.3	81
21	Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patients. British Journal of Cancer, 2007, 97, 398-404.	6.4	80
22	Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. British Journal of Cancer, 2014, 110, 2935-2944.	6.4	73
23	Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Gastroenterology, 1991, 101, 1522-1528.	1.3	72
24	Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology, 1994, 107, 1449-1456.	1.3	69
25	MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. British Journal of Cancer, 2012, 106, 1495-1498.	6.4	68
26	Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients. Current Pharmaceutical Design, 2011, 17, 1890-1910.	1.9	64
27	PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Letters, 2001, 505, 249-254.	2.8	63
28	Cytoplasmic Overexpression of HER2: A Key Factor in Colorectal Cancer. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S10811.	1.3	62
29	Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types. Oncotarget, 2017, 8, 21054-21066.	1.8	60
30	Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach Gut, 1993, 34, 80-85.	12.1	59
31	Preclinical evaluation of a novel <scp>CEA</scp> â€targeting nearâ€infrared fluorescent tracer delineating colorectal and pancreatic tumors. International Journal of Cancer, 2015, 137, 1910-1920.	5.1	55
32	Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer. Oncogene, 2016, 35, 4069-4079.	5.9	55
33	Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer, 1996, 77, 1035-1043.	4.1	53
34	EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. International Journal of Cancer, 2006, 118, 2991-2998.	5.1	49
35	Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery. Molecular Imaging and Biology, 2016, 18, 807-819.	2.6	47
36	Circulating bone morphogenetic protein levels and delayed fracture healing. International Orthopaedics, 2013, 37, 523-527.	1.9	45

#	Article	IF	CITATIONS
37	Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. European Journal of Cancer, 1995, 31, 1105-1109.	2.8	44
38	MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. British Journal of Cancer, 2008, 98, 1820-1823.	6.4	43
39	Active TGFâ€Î²1 correlates with myofibroblasts and malignancy in the colorectal adenomaâ€carcinoma sequence. Cancer Science, 2009, 100, 663-670.	3.9	42
40	uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery. Oncotarget, 2015, 6, 14260-14273.	1.8	42
41	Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. British Journal of Cancer, 1997, 75, 1793-1801.	6.4	41
42	Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. International Journal of Cancer, 2004, 109, 900-908.	5.1	40
43	Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology, 1991, 19, 231-238.	2.9	39
44	Expression of endoglin (CD105) in cervical cancer. British Journal of Cancer, 2009, 100, 1617-1626.	6.4	38
45	EpCAM as multi-tumour target for near-infrared fluorescence guided surgery. BMC Cancer, 2016, 16, 884.	2.6	36
46	Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC Cancer, 2014, 14, 269.	2.6	33
47	Injury pattern, injury severity, and mortality in 33,495 hospital-admitted victims of motorized two-wheeled vehicle crashes in The Netherlands. Journal of Trauma, 2012, 72, 1363-1368.	2.3	32
48	Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 56816-56828.	1.8	32
49	ID: 111 INFLIXIMAB INDUCES A GENOTYPE-DEPENDENT MUCOSA PROTECTIVE MATRIX METALLOPROTEINASE PHENOTYPE IN INFLAMMATORY BOWEL DISEASE. Journal of Thrombosis and Haemostasis, 2006, 4, 129-129.	3.8	30
50	Eradication of Helicobacter pylori Infection Favourably Affects Altered Gastric Mucosal MMP-9 Levels. Helicobacter, 2007, 12, 498-504.	3.5	29
51	Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thrombosis and Haemostasis, 2004, 91, 403-411.	3.4	28
52	Displaced midshaft fractures of the clavicle: non-operative treatment versus plate fixation (Sleutel-TRIAL). A multicentre randomised controlled trial. BMC Musculoskeletal Disorders, 2011, 12, 196.	1.9	28
53	Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer. Oral Oncology, 2017, 66, 1-8.	1.5	28
54	Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy. Clinical Cancer Research, 2020, 26, 3831-3842.	7.0	28

#	Article	IF	CITATIONS
55	Implant removal associated complications in children with limb fractures due to trauma. European Journal of Trauma and Emergency Surgery, 2011, 37, 623-627.	1.7	25
56	Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation. Surgical Oncology, 2019, 28, 1-8.	1.6	24
57	Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer. World Journal of Gastrointestinal Oncology, 2011, 3, 79.	2.0	22
58	Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. British Journal of Cancer, 1995, 71, 393-396.	6.4	20
59	MMP-9 Activity in Urine from Patients with Various Tumors, as Measured by a Novel MMP Activity Assay Using Modified Urokinase as a Substrate. Annals of the New York Academy of Sciences, 1999, 878, 141-149.	3.8	20
60	5-Aminosalicylic acid inhibits TGF-β1 signalling in colorectal cancer cells. Cancer Letters, 2010, 287, 82-90.	7.2	20
61	Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma. Scientific Reports, 2020, 10, 17667.	3.3	20
62	Glutathione S-transferases in liver metastases of colorectal cancer. A comparison with normal liver and primary carcinomas. Carcinogenesis, 1994, 15, 2149-2153.	2.8	19
63	Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces β-glucan-dependent CR3-dependent cellular cytotoxicity. European Journal of Immunology, 2006, 36, 977-984.	2.9	19
64	Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in Crohn's disease. Inflammatory Bowel Diseases, 2009, 15, 84-92.	1.9	19
65	Tetranectin expression in human colonic neoplasia. Histopathology, 1994, 25, 463-467.	2.9	18
66	Stromal Targets for Fluorescent-Guided Oncologic Surgery. Frontiers in Oncology, 2015, 5, 254.	2.8	18
67	EGFR and αvβ6 as Promising Targets for Molecular Imaging of Cutaneous and Mucosal Squamous Cell Carcinoma of the Head and Neck Region. Cancers, 2020, 12, 1474.	3.7	17
68	Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells. Biomarker Insights, 2017, 12, 117727191771544.	2.5	16
69	Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer. EJNMMI Research, 2020, 10, 87.	2.5	16
70	Clinical significance of stromal apoptosis in colorectal cancer. British Journal of Cancer, 2009, 101, 765-773.	6.4	15
71	In Search for Optimal Targets for Intraoperative Fluorescence Imaging of Peritoneal Metastasis From Colorectal Cancer. Biomarkers in Cancer, 2017, 9, 1179299X1772825.	3.6	14
72	Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery. International Journal of Molecular Sciences, 2017, 18, 307.	4.1	14

#	Article	IF	CITATIONS
73	Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy. OncoTargets and Therapy, 2018, Volume 11, 1655-1664.	2.0	14
74	Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review. Biomedicines, 2021, 9, 1388.	3.2	14
75	Gastric mucosal plasminogen activators inHelicobacter pylori infection. Digestive Diseases and Sciences, 1996, 41, 1577-1582.	2.3	13
76	Endothelium specific matrilysin (MMP-7) expression in human cancers. Matrix Biology, 2007, 27, 267-71.	3.6	13
77	Bone healing and Mannose-Binding Lectin. International Journal of Surgery, 2013, 11, 296-300.	2.7	13
78	Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging. Cancers, 2020, 12, 3870.	3.7	13
79	Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma. Journal of Surgical Oncology, 2018, 118, 906-914.	1.7	12
80	Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Scientific Reports, 2020, 10, 16211.	3.3	12
81	Vitamin D in Head and Neck Cancer: a Systematic Review. Current Oncology Reports, 2021, 23, 5.	4.0	12
82	Association of aneuploidy in index adenomas with metachronous colorectal adenoma development and a comparison. Cancer, 1992, 70, 2035-2043.	4.1	10
83	Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review. Cancers, 2021, 13, 557.	3.7	10
84	Endoglin/CD105-Based Imaging of Cancer and Cardiovascular Diseases: A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 4804.	4.1	10
85	High performance density gradient electrophoresis of subcellular organelles, protein complexes and proteins. Electrophoresis, 1998, 19, 1171-1178.	2.4	9
86	Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases. Cancers, 2020, 12, 1562.	3.7	9
87	Cell-Based Tracers as Trojan Horses for Image-Guided Surgery. International Journal of Molecular Sciences, 2021, 22, 755.	4.1	9
88	Fluorescence―and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma. International Journal of Cancer, 2018, 142, 2118-2129.	5.1	8
89	Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging. Molecular Diagnosis and Therapy, 2020, 24, 191-200.	3.8	8
90	A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resectionÂand surveillance of urothelial cell carcinoma. European Journal of Cancer, 2021, 146, 11-20.	2.8	8

#	Article	IF	CITATIONS
91	Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Cancers, 2021, 13, 6088.	3.7	8
92	Efficient degradation-aided selection of protease inhibitors by phage display. Biochemical and Biophysical Research Communications, 2007, 364, 549-555.	2.1	7
93	Morphological and phenotypical features of ovarian metastases in breast cancer patients. BMC Cancer, 2017, 17, 206.	2.6	7
94	Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue. Archives of Gynecology and Obstetrics, 2016, 294, 385-393.	1.7	6
95	Glycan-Based Near-infrared Fluorescent (NIRF) Imaging of Gastrointestinal Tumors: a Preclinical Proof-of-Concept In Vivo Study. Molecular Imaging and Biology, 2020, 22, 1511-1522.	2.6	6
96	Potential targets for tumor-specific imaging of vulvar squamous cell carcinoma: A systematic review of candidate biomarkers. Gynecologic Oncology, 2020, 156, 734-743.	1.4	6
97	uPAR directed-imaging of head-and-neck cancer. Oncotarget, 2017, 8, 20519-20520.	1.8	6
98	Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors. Molecular Imaging and Biology, 2021, , 1.	2.6	6
99	The effect of treatment of Helicobacter pylori infection on gastric mucosal plasminogen activators. Fibrinolysis, 1996, 10, 85-89.	0.5	5
100	CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy. Diagnostics, 2021, 11, 516.	2.6	5
101	Determination of matrilysin activity in gastrointestinal neoplasia. European Journal of Clinical Investigation, 2007, 37, 598-599.	3.4	4
102	Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Cancer, 2003, 98, 1995-1995.	4.1	3
103	An Immunohistochemical Evaluation of Tumor-Associated Glycans and Mucins as Targets for Molecular Imaging of Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 5777.	3.7	3
104	A method for semi-automated image analysis of HLA class I tumour epithelium expression in rectal cancer. European Journal of Histochemistry, 2019, 63, .	1.5	2
105	Reply to the letter to the editor: Could the use of bone morphogenetic proteins in fracture healing do more harm than good to our patients?. International Orthopaedics, 2012, 36, 685-685.	1.9	1
106	Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer. Pharmaceuticals, 2020, 13, 172.	3.8	1
107	Small Molecules for Multi-Wavelength Near-Infrared Fluorescent Mapping of Regional and Sentinel Lymph Nodes in Colorectal Cancer Staging. Frontiers in Oncology, 2020, 10, 586112.	2.8	1
108	Integrin αvβ6 as a Target for Tumor-Specific Imaging of Vulvar Squamous Cell Carcinoma and Adjacent Premalignant Lesions. Cancers, 2021, 13, 6006.	3.7	1

#	Article	IF	CITATIONS
109	ID: 108 HIGH MMP-9/NGAL COMPLEX LEVELS IN GASTRIC CANCER TISSUE ARE ASSOCIATED WITH WORSE SURVIVAL. Journal of Thrombosis and Haemostasis, 2006, 4, 127-127.	3.8	0
110	ID: 110 MATRIX METALLOPROTEINASES AND THEIR INHIBITORS IN GASTRIC CANCER: CLINICAL APPLICATION OF GENES AND PROTEINS. Journal of Thrombosis and Haemostasis, 2006, 4, 128-128.	3.8	0
111	Endoglin as an Important Regulator of Colorectal Cancer Invasion and Metastasis. Gastroenterology, 2017, 152, S87.	1.3	0
112	Welcome to Surgeries: A New Open Access Platform for Clinical and Experimental Research and Developments in All Fields of Surgery. Surgeries, 2020, 1, 1-1.	0.6	0
113	NIR Fluorescence Imaging of Colon Cancer With cRGD-ZW800-1—Response. Clinical Cancer Research, 2021, 27, 4938-4938.	7.0	0
114	Abstract 4130: Dual targeting of VEGF and endoglin inhibits tumor angiogenesis and metastatic spread. , 2015, , .		0
115	Abstract P6-01-01: Immunohistochemical staining andin vitroanalysis of HER2-positive breast cancer using trastuzumab and pertuzumab to develop an appropriate tracer in image-guided surgery. , 2019, , .		0
116	Abstract 291: Synergistic inhibition of cancer invasion and metastasis by combined anti-PD1-TRC105-mediated Endoglin targeting on cancer-associated fibroblasts and endothelial cells. , 2019, , .		0
117	EP952â€Novel molecular target selection for tumour-specific imaging of metastases from epithelial ovarian cancer. , 2019, , .		0
118	Abstract 291: Synergistic inhibition of cancer invasion and metastasis by combined anti-PD1-TRC105-mediated Endoglin targeting on cancer-associated fibroblasts and endothelial cells. , 2019, , .		0